Top Rated Devices Suitable for PRDX5

18 months, P = 0.066). But KRAS codon 12 mutations had no significant effect on the latency (Wild type vs. codon 12 mutation, PRDX5 18 vs. 16 months, P = 0.775; codon 12 mutation vs. codon 13 mutation, 16 vs. 13 months, P = 0.277). Additional details are provided in Figure 2. Figure 1 Timing of metachronous distant metastases. 50% of metachronous metastases occurred within 16 months, 75% occurred within 28 months, and 95% within 56 months after primary tumor resection. Figure 2 KRAS codon 12 and codon 13 mutations affected the latency of metachronous distant metastases after primary tumor resection. There were potential significant difference between patients with KRAS wild type and codon 13 mutation (P = 0.066). Median: median ... After resections of metastases, patients origionally diagnosed with metachronous metastases had longer overall survival time than synchronous metastases (median, 43 vs. 23 months, P = 0.050, details in Figure 3). The overall survival after occurrence of metachronous metastases is also showed in Figure 4. The survival curve showed no significant differences between patients with find more wild-type KRAS, codon 12 mutations and codon 13 mutations. Multivariate Cox regression in Table 6 showed that radical resection of metachronous metastases was a significant protective factor for long time survival (HR = 0.280, P = 0.002). Chemotherapy MCC950 order and TACE/TAI had similar effects, but were both far less effective than radical surgery. The survival curve in Figure 5 also shows that radical resection of metastases resulted in a subsequent median survival of 43 months, significantly longer than chemotherapy alone (median 6 months, P